These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
374 related articles for article (PubMed ID: 31281155)
1. [Allogeneic hematopoietic stem cell transplantation for hematological malignancies: an algorithm for donor selection]. Sugita J Rinsho Ketsueki; 2019; 60(6):626-634. PubMed ID: 31281155 [TBL] [Abstract][Full Text] [Related]
2. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Gaballa S; Ge I; El Fakih R; Brammer JE; Kongtim P; Tomuleasa C; Wang SA; Lee D; Petropoulos D; Cao K; Rondon G; Chen J; Hammerstrom A; Lombardi L; Alatrash G; Korbling M; Oran B; Kebriaei P; Ahmed S; Shah N; Rezvani K; Marin D; Bashir Q; Alousi A; Nieto Y; Qazilbash M; Hosing C; Popat U; Shpall EJ; Khouri I; Champlin RE; Ciurea SO Cancer; 2016 Nov; 122(21):3316-3326. PubMed ID: 27404668 [TBL] [Abstract][Full Text] [Related]
3. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. Bashey A; Zhang X; Sizemore CA; Manion K; Brown S; Holland HK; Morris LE; Solomon SR J Clin Oncol; 2013 Apr; 31(10):1310-6. PubMed ID: 23423745 [TBL] [Abstract][Full Text] [Related]
4. Single Antigen-Mismatched Unrelated Hematopoietic Stem Cell Transplantation Using High-Dose Post-Transplantation Cyclophosphamide Is a Suitable Alternative for Patients Lacking HLA-Matched Donors. Jorge AS; Suárez-Lledó M; Pereira A; Gutierrez G; Fernández-Avilés F; Rosiñol L; Llobet N; Solano T; Urbano-Ispízua Á; Rovira M; Martínez C Biol Blood Marrow Transplant; 2018 Jun; 24(6):1196-1202. PubMed ID: 29410343 [TBL] [Abstract][Full Text] [Related]
5. Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts. Raiola AM; Dominietto A; di Grazia C; Lamparelli T; Gualandi F; Ibatici A; Bregante S; Van Lint MT; Varaldo R; Ghiso A; Gobbi M; Carella AM; Signori A; Galaverna F; Bacigalupo A Biol Blood Marrow Transplant; 2014 Oct; 20(10):1573-9. PubMed ID: 24910379 [TBL] [Abstract][Full Text] [Related]
6. Alternative Donor Graft Sources for Adults with Hematologic Malignancies: A Donor for All Patients in 2017! Kindwall-Keller TL; Ballen KK Oncologist; 2017 Sep; 22(9):1125-1134. PubMed ID: 28546462 [TBL] [Abstract][Full Text] [Related]
8. Decreased Mortality in 1-Year Survivors of Umbilical Cord Blood Transplant vs. Matched Related or Matched Unrelated Donor Transplant in Patients with Hematologic Malignancies. Bohannon L; Tang H; Page K; Ren Y; Jung SH; Artica A; Britt A; Islam P; Siamakpour-Reihani S; Giri V; Lew M; Kelly M; Choi T; Gasparetto C; Long G; Lopez R; Rizzieri D; Sarantopoulos S; Chao N; Horwitz M; Sung A Transplant Cell Ther; 2021 Aug; 27(8):669.e1-669.e8. PubMed ID: 33991725 [TBL] [Abstract][Full Text] [Related]
9. [Comparison of clinical efficacy between HLA-mismatched related and HLA-matched unrelated donor hematopoietic stem cell transplantation for hematopoietic malignancies]. Yu S; Dai M; Sun J; Fan Z; Huang F; Zhang Y; Jiang Q; Zhou H; Xu D; Meng F; Liu Q Zhonghua Xue Ye Xue Za Zhi; 2014 Sep; 35(9):826-30. PubMed ID: 25246252 [TBL] [Abstract][Full Text] [Related]
10. High-Dose Cyclophosphamide and Tacrolimus as Graft-versus-Host Disease Prophylaxis for Matched and Mismatched Unrelated Donor Transplantation. Pedraza A; Jorge S; Suárez-Lledó M; Pereira A; Gutiérrez-García G; Fernández-Avilés F; Rosiñol L; Llobet N; Solano T; Urbano-Ispízua Á; Rovira M; Martínez C Transplant Cell Ther; 2021 Jul; 27(7):619.e1-619.e8. PubMed ID: 33895157 [TBL] [Abstract][Full Text] [Related]
11. Single Cord Blood Transplantation Versus HLA-Haploidentical-related Donor Transplantation Using Posttransplant Cyclophosphamide in Patients With Hematological Malignancies. Wada F; Kanda J; Yoshioka S; Ishikawa T; Akasaka T; Ueda Y; Hirata H; Arai Y; Yago K; Anzai N; Watanabe M; Ikeda T; Yonezawa A; Imada K; Itoh M; Kitano T; Takeoka T; Hishizawa M; Nohgawa M; Arima N; Asagoe K; Kondo T; Takaori-Kondo A; Transplantation; 2022 Jun; 106(6):1279-1287. PubMed ID: 34935764 [TBL] [Abstract][Full Text] [Related]
12. T-cell replete haploidentical donor transplantation using post-transplant CY: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor. Bashey A; Solomon SR Bone Marrow Transplant; 2014 Aug; 49(8):999-1008. PubMed ID: 24842530 [TBL] [Abstract][Full Text] [Related]
13. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors. Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174 [TBL] [Abstract][Full Text] [Related]
14. Haploidentical Transplantation with Post-Transplant Cyclophosphamide versus Unrelated Donor Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. Arcuri LJ; Aguiar MTM; Ribeiro AAF; Pacheco AGF Biol Blood Marrow Transplant; 2019 Dec; 25(12):2422-2430. PubMed ID: 31386903 [TBL] [Abstract][Full Text] [Related]
15. Haploidentical Versus Mismatched Unrelated Donor Hematopoietic Cell Transplantation: HLA Factors and Donor Age Considerations. Mehta RS; Petersdorf EW; Wang T; Lee SJ Transplant Cell Ther; 2024 Sep; 30(9):909.e1-909.e11. PubMed ID: 38992469 [TBL] [Abstract][Full Text] [Related]
16. Real-World Data Showing Trends and Outcomes by Race and Ethnicity in Allogeneic Hematopoietic Cell Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. Auletta JJ; Kou J; Chen M; Bolon YT; Broglie L; Bupp C; Christianson D; Cusatis RN; Devine SM; Eapen M; Hamadani M; Hengen M; Lee SJ; Moskop A; Page KM; Pasquini MC; Perez WS; Phelan R; Riches ML; Rizzo JD; Saber W; Spellman SR; Stefanski HE; Steinert P; Tuschl E; Yusuf R; Zhang MJ; Shaw BE Transplant Cell Ther; 2023 Jun; 29(6):346.e1-346.e10. PubMed ID: 36924931 [TBL] [Abstract][Full Text] [Related]
17. Mismatched unrelated alternative donors for hematological malignancies. Sebastian Schäfer H; Finke J Semin Hematol; 2016 Apr; 53(2):77-81. PubMed ID: 27000730 [TBL] [Abstract][Full Text] [Related]
19. Treatment of hematological malignancies with nonmyeloablative, HLA-haploidentical bone marrow transplantation and high dose, post-transplantation cyclophosphamide. Munchel AT; Kasamon YL; Fuchs EJ Best Pract Res Clin Haematol; 2011 Sep; 24(3):359-68. PubMed ID: 21925089 [TBL] [Abstract][Full Text] [Related]
20. Donor Type and Disease Risk Predict the Success of Allogeneic Hematopoietic Cell Transplantation: A Single-Center Analysis of 613 Adult Hematopoietic Cell Transplantation Recipients Using a Modified Composite Endpoint. Solh M; Zhang X; Connor K; Brown S; Morris LE; Holland HK; Bashey A; Solomon SR Biol Blood Marrow Transplant; 2017 Dec; 23(12):2192-2198. PubMed ID: 28864140 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]